Ligand Pharmaceuticals LGND Convertible Preferred Stock Authorized Shares
Convertible Preferred Stock Authorized Shares at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's convertible preferred stock authorized shares.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's convertible preferred stock authorized shares?
- Ligand Pharmaceuticals (LGND) reported convertible preferred stock authorized shares of 5M in Q1 2026.
- How has Ligand Pharmaceuticals's convertible preferred stock authorized shares changed year-over-year?
- Ligand Pharmaceuticals's convertible preferred stock authorized shares decreased by 0.0% year-over-year, from 5M to 5M.
- What is the long-term trend for Ligand Pharmaceuticals's convertible preferred stock authorized shares?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's convertible preferred stock authorized shares has grown at a 0.0% compound annual growth rate (CAGR), from 5M to 5M.
- What does convertible preferred stock authorized shares mean?
- Maximum number of convertible preferred shares the company is authorized to issue under its corporate charter.